GlassScriptPhysician profile
Olajide O Benson
NPI 1417191289
$13,719.28
in general payments reported to CMS, 2019-2025
39 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,749 · 2020: $631 · 2021: $1,896 · 2022: $1,585 · 2023: $3,069 · 2024: $1,367 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,854 · Travel and Lodging: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,854.29 |
| Travel and Lodging | $1,002.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,581.58 | 2019-2025 | Mavenclad, Mavenclad |
| Livanova USA, INC. | $1,577.58 | 2019 | |
| Medtronic, INC. | $1,462.31 | 2022-2023 | Synchromedii |
| Medtronic USA, INC. | $1,275.19 | 2019 | |
| Neurocrine Biosciences, INC. | $750.37 | 2019-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $744.05 | 2021-2025 | Qulipta, Ubrelvy |
| Biogen, INC. | $571.52 | 2019-2023 | Vumerity, Spinraza |
| Amgen INC. | $552.49 | 2020-2022 | |
| Pfizer INC. | $546.60 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $514.43 | 2019-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $431.98 | 2019-2025 | |
| Lilly USA, LLC | $413.94 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Biohaven Pharmaceutical Holding Company LTD. | $398.21 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $362.90 | 2020-2021 | |
| Sk Life Science, INC. | $343.06 | 2020-2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $338.44 | 2019-2025 | |
| Ucb, INC. | $251.15 | 2022-2025 | Nayzilam, Rystiggo, Briviact |
| Argenx US, INC. | $237.68 | 2024-2025 | Vyvgart Hytrulo |
| Allergan, INC. | $176.44 | 2019-2020 | |
| Neurelis, INC. | $163.29 | 2020-2024 | Valtoco |
| Genzyme Corporation | $133.84 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $115.14 | 2021-2025 | Ultomiris |
| Celgene Corporation | $104.92 | 2021-2024 | Zeposia |
| Ceribell, INC. | $95.90 | 2019 | |
| Janssen Biotech, INC. | $88.83 | 2025 | |
| Penumbra, INC. | $69.83 | 2020 | |
| Lundbeck LLC | $66.89 | 2025 | Vyepti |
| Chiesi USA, INC. | $51.85 | 2019 | |
| Jazz Pharmaceuticals INC. | $47.44 | 2022-2024 | |
| Amneal Pharmaceuticals LLC | $42.88 | 2022-2023 | Rytary |
| Vanda Pharmaceuticals INC. | $36.29 | 2025 | Ponvory |
| Acorda Therapeutics, INC | $36.14 | 2023 | Inbrija |
| Corium, LLC | $28.43 | 2023 | Adlarity |
| Arbor Pharmaceuticals, INC. | $23.70 | 2021 | |
| Horizon Therapeutics Plc | $20.23 | 2023 | Uplizna |
| Acadia Pharmaceuticals INC | $17.97 | 2025 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $17.85 | 2020 | |
| Genentech USA, INC. | $16.13 | 2025 | Ocrevus Zunovo |
| Kyowa Kirin, INC. | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olajide Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.